Search Results
Keyword：isotope enrichment technology
U.S. Marathon Fusion Demonstrates Hydrogen and Lithium Isotope Enrichment Technology
U.S.-based Marathon Fusion announced on August 27 that it has successfully demonstrated hydrogen and lithium isotope enrichment technology using its proprietary plasma centrifuge. The company stated that this advancement addresses the fuel cycle needs of fusion energy and related isotope supply requirements. In the deuterium-tritium fusion pathway, hydrogen isotope processing is critical to the continuous operation of fusion devices, while lithium isotope enrichment is closely tied to tritium production. The U.S. Department of Energy (DOE) released its "Fusion Science and Technology Roadmap" in June of this year, which identifies tritium processing as one of the core challenges, noting that related progress is essential for achieving sustained deuterium-tritium fusion operation and validating fusion as a large-scale energy form...
2026-08-28
ASP Isotopes Plans Commercial Delivery of Multiple Stable Isotopes in Second Half of 2026
ASP Isotopes Inc. recently presented its expansion plans for isotope production, radiopharmaceuticals, and helium operations at Canaccord Genuity's 46th Annual Growth Conference. The company aims to begin commercial delivery of stable isotopes including silicon-28, carbon-14, and ytterbium-176 in the second half of 2026. Victor Petkov, the company's Chief Commercial Officer, stated that ASP Isotopes is leveraging its proprietary enrichment technology to serve electronics, nuclear medicine, and nuclear fuel-related markets. Currently, the company operates three production facilities in Pretoria, South Africa, primarily producing silicon-28 for semiconductor applications, as well as carbon-14 and ytterbium-176 for nuclear medicine-related uses. Regarding isotope supply...
2026-08-13
ASP Isotopes PET Lab Revenue Grows Over 50% in First Half of Year, Isotope Enrichment Facilities Advance Toward Commercial Production
ASP Isotopes Inc. recently released a letter to shareholders outlining operational progress across its business segments ahead of the company's second-quarter 2026 financial results announcement. The company stated that its PET lab segment achieved organic revenue growth of more than 50% in the first half of 2026 compared to the same period in 2025. Based on current expectations, the segment's full-year 2026 revenue is projected to be approximately $14 million, up from $6 million in 2025. PET-related operations are typically closely associated with radiopharmaceutical preparation, molecular imaging, and nuclear medicine diagnostic applications. On the isotope front, ASP Isotopes stated that its silicon-28 and ytterbium-176 enrichment facilities have entered the final stage before commercial production, with first deliveries expected in the second half of 2026...
2026-08-05